Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo may boost standard liver cancer procedure

NCT ID NCT04712643

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to a standard liver cancer procedure called TACE helps people with untreated liver cancer live longer or delay the cancer from getting worse. About 342 adults with liver cancer who are not candidates for curative treatments will be randomly assigned to receive either TACE alone or TACE plus the drug combination. The goal is to see if the combination improves survival and delays the need for more intensive treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

342 people

The number who actually took part.

Started

Mar 2021

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of HCC by histology/ cytology or clinical criteria * Eligible for TACE treatment * No prior systemic therapy for HCC, especially immunotherapy * No prior locoregional therapy to the target lesion(s) * At least one measurable untreated lesion * ECOG Performance Status of 0-1 * Child-Pugh class A Exclusion Criteria: * Evidence of Vp3/4 and hepatic vein tumor thrombus (HVTT) * Evidence of extrahepatic spread (EHS) * Being a candidate for curative treatments * Any condition representing a contraindication to TACE as determined by the investigators * Active or history of autoimmune disease or immune deficiency * Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding * A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment * Evidence of bleeding diathesis or significant coagulopathy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Aichi Cancer Center

    Aichi, 464-8681, Japan

  • Anhui Provincial Hospital

    Anhui, 230001, China

  • Beijing Tsinghua Changgung Hospital

    Beijing, 102218, China

  • Beijing You An Hospital

    Beijing, 100069, China

  • Chiba University Hospital

    Chiba, 260-8677, Japan

  • Fudan University Shanghai Cancer Center

    Shanghai, 200120, China

  • Fujian Cancer Hospital

    Fuzhou, 350014, China

  • Guangxi Cancer Hospital of Guangxi Medical University

    Nanning, 530021, China

  • Harbin Medical University Cancer Hospital

    Harbin, 150081, China

  • Henan Cancer Hospital

    Zhengzhou, 450008, China

  • Hiroshima University Hospital

    Hiroshima, 734-8551, Japan

  • Hunan Cancer Hospital

    Changsha, 410013, China

  • Jiangsu Cancer Hospital

    Nanjing, 210009, China

  • Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)

    Nanjing, 210029, China

  • Kanagawa Cancer Center

    Kanagawa, 241-8515, Japan

  • Kindai University Hospital

    Osaka, 589-8511, Japan

  • Kitasato University Hospital

    Kanagawa, 252-0375, Japan

  • Kurume University Hospital

    Fukuoka, 830-0011, Japan

  • Mengchao Hepatobiliary Hospital Of Fujian Medical University

    Fuzhou, 350025, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, 510515, China

  • Peking University First Hospital

    Beijing, 100034, China

  • Peking University People's Hospital

    Beijing, 100044, China

  • Renji Hospital Shanghai Jiaotong University School of Medicine

    Shanghai, 200127, China

  • Shengjing Hospital of China Medical University

    Shenyang, 110004, China

  • Southwest Hospital , Third Military Medical University

    Chongqing, 400038, China

  • Sun Yet-sen University Cancer Center

    Guangzhou, 510060, China

  • The 900th Hospital of PLA joint service support force

    Fuzhou, 110016, China

  • The First Affiliate Hospital of Guangxi Medical University

    Nanning, 530021, China

  • The First Affiliated Hospital Of Fujian Medical University

    Fuzhou, 350005, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • The First Affiliated Hospital, Chongqing Medical University

    Chongqing, 400016, China

  • The University of Osaka Hospital

    Osaka, 565-0871, Japan

  • Tianjin Cancer Hospital

    Tianjin, 300060, China

  • Toranomon Hospital

    Tokyo, 105-8470, Japan

  • West China Hospital, Sichuan University

    Chengdu, China

  • Xi'an Inernational Medical Center Hospital

    Xi'an, China

  • Yokohama City University Medical Center

    Kanagawa, 232-0024, Japan

  • Zhejiang Cancer Hospital

    Hangzhou, 310022, China

  • Zhongshan Hospital Fudan Unvierstiy

    Shanghai, China

  • Zhuhai People's Hospital

    Zhuhai, 519099, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.